Pyrrole Derivatives Modulating Alpha-7 Nicotinic Receptors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current nicotinic acetylcholine receptor (nAChR) ligands, particularly α7 nAChR agonists, face challenges with sustained activation leading to desensitization and adverse effects, while positive allosteric modulators demonstrate weak activity and limited access to the central nervous system, necessitating the development of new compounds that selectively modulate α7 nAChRs for improved efficacy and reduced adverse effects.
Innovation Solution
Development of compounds with specific structures, such as those represented by formulas (I) and (II), which act as positive allosteric modulators to enhance endogenous acetylcholine transmission without direct receptor activation, thereby modulating α7 nAChR activity for treating conditions like Alzheimer's disease, schizophrenia, and pain, while minimizing side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If α7 nAChR agonists are used to treat cognitive disorders and neurodegenerative diseases, then therapeutic efficacy is improved, but desensitization and adverse effects occur due to sustained activation
Solution Approach 1:
Instead of using agonists that directly activate the receptor (causing sustained activation and desensitization), the patent employs positive allosteric modulators that enhance endogenous acetylcholine transmission. This inverted approach—modulating receptor sensitivity rather than directly stimulating it—maintains therapeutic efficacy while avoiding desensitization and adverse effects associated with continuous agonist exposure
2Object-generated harmful factors
If positive allosteric modulators are used to avoid direct receptor activation, then adverse effects are reduced, but activity and CNS access are weakened
Solution Approach 1:
The patent systematically optimizes molecular parameters of the positive allosteric modulators, including substituent groups (R1-R6), ring structures (A), and linker configurations. By adjusting these structural parameters, the compounds achieve enhanced potency, improved blood-brain barrier penetration, and sufficient CNS access while maintaining their mechanism as allosteric modulators that avoid direct agonist-induced desensitization
Data Source
AI summary
The invention relates to a series of substituted pyrrole derivatives, compositions comprising the same, and methods of treating conditions and disorders using such compounds and compositions.